Healthcare
Imugene Limited (ASX:IMU)
Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology
Market Price : AUD 0.445-0.01 (2.198%)
(as on 2021-10-23 03:55:41)
| Previous Close | Open | Close* | Day Range | 52 WEEK HIGH LOW |
|---|---|---|---|---|
| 0.455 | 0.46 | 0.445 | 0.445L 0.465 H | 0.054L 0.515 H |
| Last Trade | 0.445 |
|---|---|
| Change% | -2.1978 |
| 52 W H/L | 0.515/0.054 |
| EBITDA | -18.24 M |
|---|---|
| NPAT After Abnormal Items | -18.455 M |
| Equity | 65.018 M |
| ROE% | -28.39% |
| Total Liabilities | 6.791 M |
|---|---|
| Total Revenue | 7.282 M |
| Cash and Cash Equivalents | 29.487 M |
Stock Information
| Share price | 0.445 |
|---|---|
| Market Cap | 2.445 B |
| Price/Gross Cash Flow | -137.41 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 4.963 B | 52-Week Range | 0.054-0.515 |
| P/E ratio | 0.000 |
|---|---|
| Sector P/E | -- | EPS | -0.40 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -- |
| Gross Cash Flows Per Share | -0.00 |
| Net Gearing | -44.94% |
| Gross DPS (AUD) | 0 |
|---|---|
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 0.000 |
| Net Tangible Asset (NTA) | 0.01 |
| Sales Per Share | 0.00 |
| Book Value Per Share | 0.01 |
Announcements
About Company
Imugene Limited (ASX:IMU) is an Australia-headquartered clinical stage immuno-oncology firm which is in the process of developing a wide array of new treatments that attempt to activate the cancer patients’ immune system to detect and remove tumours. The Company intends to improve and transform the lives of cancer-bearing patients who need effective treatments.
Imugene is backed by a leading team of international cancer experts who hold extensive experience in advancing new cancer therapies. The Company’s efficient and strong management team provides confidence in its ability to discover and manage the development and sales process for its products.
The Company’s clinical pipeline comprises multiple immunotherapy B-Cell vaccine candidates and an Oncolytic Virotherapy CF33, which intend to treat a range of cancers along with the standard of care drugs as well as emerging immunotherapies. The B-cell immunotherapies comprise PD1-Vaxx and two HER2 B-cell immunotherapies - HER-Vaxx and B-Vaxx.
PD-1 Vaxx, or the PD-1 B-cell immunotherapy, aims to induce the patient’s body to generate polyclonal antibodies which block PD-1 signalling, and therefore, create an anticancer effect akin to Opdivo, Keytruda and the other immune checkpoint inhibitors, which have transitioned the treatment for a range of cancers. Besides, HER-Vaxx has been designed for treating tumours which over-express the HER-2 protein, like gastric, lung, pancreatic, breast, and ovarian cancers. Akin to HER-Vaxx, B-Vaxx has also been designed for treating tumours which over-express the HER-2 protein.
Acquired by the Company in November 2019, CF33 was developed by renowned Professor Yuman Fong at City of Hope (COH) Cancer Centre based in Los Angeles, California. CF33 is identified as a chimeric vaccinia poxvirus in the area of oncolytic virotherapy that comes in two different forms: CHECKVacc and Vaxinia. Through the use of CF33, Imugene hopes to bolster the clinical benefits and quality of living for patients suffering from cancers that are difficult to treat through current therapeutic approaches.
Corporate Information
|
|
|
|
Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053
03 9824 5254
Dividends
| Ex-Dividend Date | Franking | DPS (AUD) | Dividend Yield |
|---|---|---|---|
| 30/06/2021 | -- | 0.000 | 0.00% |
| 30/06/2020 | -- | 0.000 | 0.00% |
| 30/06/2019 | -- | 0.000 | 0.00% |
| 30/06/2018 | -- | 0.000 | 0.00% |
| 30/06/2017 | -- | 0.000 | 0.00% |
| 30/06/2016 | -- | 0.000 | 0.00% |
| 30/06/2015 | -- | 0.000 | 0.00% |
| 30/06/2014 | -- | 0.000 | 0.00% |
| 30/06/2013 | -- | 0.000 | 0.00% |
| 30/06/2012 | -- | 0.000 | 0.00% |
Event Calendar
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Annual) | 2022-10-03 | 2022 |
| Report (Prelim) | 2022-08-29 | 2022 |
| Report (Interim) | 2022-02-25 | 2022 |
Financials
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Trading Revenue | -- | -- | -- | -- | -- |
| Other Revenue | 7.282 M | 4.074 M | 4.205 M | 1.841 M | 1.164 M |
| Total Revenue | 7.282 M | 4.074 M | 4.205 M | 1.841 M | 1.164 M |
| Interest Income | 126,565 | 302,186 | 414,893 | 94,327 | 35,429 |
| Interest Expenses | -116,056 | -5,029 | -6,108 | 0 | 0 |
| Expenses | -25.643 M | -13.308 M | -12.328 M | -5.866 M | -3.704 M |
| EBITDA | -18.362 M | -9.234 M | -8.123 M | -4.025 M | -2.54 M |
| Depreciation and Amortization | -104,203 | -82,495 | -63,259 | -2,680 | -1,743 |
| Depreciation | -104,203 | -82,495 | -63,259 | -2,680 | -1,743 |
| Amortisation | 0 | 0 | 0 | 0 | 0 |
| EBIT | -18.466 M | -9.316 M | -8.186 M | -4.028 M | -2.542 M |
| Pre Tax Profit | -18.455 M | -9.019 M | -7.777 M | -3.934 M | -2.507 M |
| Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Profit After Tax | -18.455 M | -9.019 M | -7.777 M | -3.934 M | -2.507 M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Preference Dividend | 0 | 0 | 0 | 0 | 0 |
| Net Abnormal Items | 0 | -1.489 M | 1,726 | 0 | 0 |
| Reported Net Profit After Abnormal Items | -18.455 M | -10.508 M | -7.775 M | -3.934 M | -2.507 M |
| Ending Shares | 4.963 B | 4.426 B | 3.61 B | 2.855 B | 2.387 B |
| Weighted Average Shares | 4.664 B | 4.075 B | 3.582 B | 2.638 B | 2.088 B |
| EPS After Abnormal Items (cents) | -0.4 | -0.26 | -0.22 | -0.15 | -0.12 |
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Total Current Assets | 36.319 M | 34.495 M | 23.424 M | 9.833 M | 6.054 M |
| Total Non Current Assets | 35.49 M | 30.71 M | 7.356 M | 7.081 M | 6.623 M |
| Total Assets | 71.809 M | 65.205 M | 30.779 M | 16.914 M | 12.678 M |
| Total Current Liabilities | 4.457 M | 2.899 M | 2.424 M | 438,240 | 297,493 |
| Total Non Current Liabilities | 2.334 M | 2.499 M | 1.061 M | 1.001 M | 985,450 |
| Total Liabilities | 6.791 M | 5.399 M | 3.485 M | 1.439 M | 1.283 M |
| Net Assets | 65.018 M | 59.806 M | 27.295 M | 15.475 M | 11.395 M |
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Net Operating Cash | -13.28 M | -10.438 M | -7.909 M | -4.462 M | -2.673 M |
| Net Invested Cash | -5.326 M | -1.207 M | 247,392 | -460,676 | -2,340 |
| Net Financing Cash Flows | 17.985 M | 22.707 M | 18.773 M | 7.93 M | 5.928 M |
| Beginning Cash | 30.107 M | 19.048 M | 7.822 M | 4.814 M | 1.583 M |
| End Cash Position | 29.487 M | 30.107 M | 19.048 M | 7.822 M | 4.814 M |
| Exchange Rate Adjustments | 1,353 | -3,898 | 115,072 | 0 | -21,151 |
| Other Cash Adjustments | 0 | 0 | 0 | 0 | 0 |
| Ending Cash | 29.487 M | 30.107 M | 19.048 M | 7.822 M | 4.814 M |
© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.